Skip to main content
Top
Published in: BMC Infectious Diseases 1/2006

Open Access 01-12-2006 | Research article

Microbiology of airway disease in a cohort of patients with Cystic Fibrosis

Authors: Antonietta Lambiase, Valeria Raia, Mariassunta Del Pezzo, Angela Sepe, Vincenzo Carnovale, Fabio Rossano

Published in: BMC Infectious Diseases | Issue 1/2006

Login to get access

Abstract

Background

Recent reports document an increasing incidence of new Gram-negative pathogens such as Stenotrophomonas maltophilia and Alcaligenes xylosoxidans isolated from patients with Cystic Fibrosis, along with an increase in common Gram-negative pathogens such as Pseudomonas aeruginosa and Burkholderia cepacia complex. Furthermore, the increase in multidrug-resistance of such organisms makes the therapeutic management of these patients more problematic. Therefore, careful isolation and identification, and accurate studies of susceptibility to antibiotics are critical for predicting the spread of strains, improving therapeutic measures and facilitating our understanding of the epidemiology of emerging pathogens. The first aim of this study was to determine the incidence and the prevalence of colonization by Gram-negative organisms isolated from respiratory samples of Cystic Fibrosis patients in the Regional Referral Cystic Fibrosis Centre of Naples; the second was to evaluate the spectrum of multidrug-resistance of these organisms.

Methods

Patients (n = 300) attending the Regional Cystic Fibrosis Unit were enrolled in this study over 3 years. Sputum was processed for microscopic tests and culture. An automated system, Phoenix (Becton Dickinson, Sparks, Maryland, USA), was used for phenotypic identification of all strains; the API 20 NE identification system (bioMérieux, Marcy l'Etoile, France) was used when the identification with the Phoenix system was inaccurate. A PCR-RFLP method was used to characterize the organisms in the Burkholderia cepacia complex. A chemosusceptibility test on microbroth dilutions (Phoenix) was used. Primary outcomes such as FEV1 were correlate with different pathogens.

Results

During the period of study, 40% of patients was infected by Pseudomonas aeruginosa, 7% by Burkholderia cepacia complex, 11% by Stenotrophomonas maltophilia and 7% by Alcaligenes xylosoxidans. Of the strains isolated, 460 were multidrug-resistant. Multiresistant were Pseudomonas aeruginosa and Burkholderia cepacia complex.

Conclusion

The results confirm previously reported data; in particular, they show an increase the isolation of non-fermentative Gram-negative bacteria in Cystic Fibrosis patients. They also demonstrate increased resistance to antibiotics. Beta-lactams are rarely effective, with exception of ceftazidime, which is the most efficacious agent against multiresistant strains. Aminoglycosides and quinolones are poorly efficacious.
Literature
1.
go back to reference Ramsey BW: Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996, 335: 179-188. 10.1056/NEJM199607183350307.CrossRefPubMed Ramsey BW: Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996, 335: 179-188. 10.1056/NEJM199607183350307.CrossRefPubMed
2.
go back to reference Boucher RC: New concepts in the pathogenesis of cystic fibrosis lung disease. Eur Resp J. 2004, 23: 146-55. 10.1183/09031936.03.00057003.CrossRef Boucher RC: New concepts in the pathogenesis of cystic fibrosis lung disease. Eur Resp J. 2004, 23: 146-55. 10.1183/09031936.03.00057003.CrossRef
4.
go back to reference Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR: Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998, 27: 158-163.CrossRefPubMed Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR: Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998, 27: 158-163.CrossRefPubMed
5.
go back to reference Rajan S, Saiman L: Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect. 2002, 17 (1): 47-56. 10.1053/srin.2002.31690.CrossRefPubMed Rajan S, Saiman L: Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect. 2002, 17 (1): 47-56. 10.1053/srin.2002.31690.CrossRefPubMed
6.
go back to reference Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL: Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 2002, 165 (7): 904-910.CrossRefPubMed Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL: Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 2002, 165 (7): 904-910.CrossRefPubMed
7.
go back to reference Goss CH, Mayer-Hamblett N, Autken ML, Rubenfeld GD, Ramsey BW: Association between Stenotrophomonas maltophilia and lung function in Cystic Fibrosis. Thorax. 2004, 59: 955-959. 10.1136/thx.2003.017707.CrossRefPubMedPubMedCentral Goss CH, Mayer-Hamblett N, Autken ML, Rubenfeld GD, Ramsey BW: Association between Stenotrophomonas maltophilia and lung function in Cystic Fibrosis. Thorax. 2004, 59: 955-959. 10.1136/thx.2003.017707.CrossRefPubMedPubMedCentral
8.
go back to reference Saiman L, MacDonald N, Burns JL, Hoiby N, Speert DP, Weber D: Infection control in cystic fibrosis: pratical recommendations for the hospital, clinic, and social setting. Am J Infect Control. 2000, 28: 381-385. 10.1067/mic.2000.106337.CrossRefPubMed Saiman L, MacDonald N, Burns JL, Hoiby N, Speert DP, Weber D: Infection control in cystic fibrosis: pratical recommendations for the hospital, clinic, and social setting. Am J Infect Control. 2000, 28: 381-385. 10.1067/mic.2000.106337.CrossRefPubMed
9.
go back to reference Kretzer EK, Larson EL: Behavioral interventions to improve infection control practices. Am J Infect Control. 1998, 26: 245-253.CrossRefPubMed Kretzer EK, Larson EL: Behavioral interventions to improve infection control practices. Am J Infect Control. 1998, 26: 245-253.CrossRefPubMed
10.
go back to reference Conway SP, Brownlee KG, Denton M, Peckham DG: Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med. 2003, 2 (4): 321-332.CrossRefPubMed Conway SP, Brownlee KG, Denton M, Peckham DG: Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med. 2003, 2 (4): 321-332.CrossRefPubMed
11.
go back to reference Banerjee D, Stableforth D: The treatment of respiratory Pseudomonas infection in cystic fibrosis: what drug and which way?. Drugs. 2000, 60 (5): 1053-1064.CrossRefPubMed Banerjee D, Stableforth D: The treatment of respiratory Pseudomonas infection in cystic fibrosis: what drug and which way?. Drugs. 2000, 60 (5): 1053-1064.CrossRefPubMed
12.
go back to reference Frederiksen B, Koch C, Høiby N: Changing epidemiology of Pseudomonas aeruginosa infection in Danish Cystic Fibrosis patients (1974–1995). Pediatr Pulmonol. 1999, 28: 159-166. 10.1002/(SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO;2-1.CrossRefPubMed Frederiksen B, Koch C, Høiby N: Changing epidemiology of Pseudomonas aeruginosa infection in Danish Cystic Fibrosis patients (1974–1995). Pediatr Pulmonol. 1999, 28: 159-166. 10.1002/(SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO;2-1.CrossRefPubMed
13.
go back to reference Saiman L, MacDonald NE, Whittier S: The microbiological basis for antimicrobial therapy. Tenth Annual North American Cystic Fibrosis Conference. Cystic Fibrosis Foundation: 24. 1996, October ; Orlando Saiman L, MacDonald NE, Whittier S: The microbiological basis for antimicrobial therapy. Tenth Annual North American Cystic Fibrosis Conference. Cystic Fibrosis Foundation: 24. 1996, October ; Orlando
14.
go back to reference McDowell A, Mahenthiralingam E, Moore JE, Dunbar KEA, Kevun Webb A, Dodd ME, Lorraine Martin S, Cherie Millar B, Scott CJ, Crowe M, Stuart Elborn J: PCR-Based Detection and Identification of Burkholderia cepacia Complex Pathogens in Sputum from Cystic Fibrosis Patients. J Clin Microbiol. 2001, 39 (12): 4247-4255. 10.1128/JCM.39.12.4247-4255.2001.CrossRefPubMedPubMedCentral McDowell A, Mahenthiralingam E, Moore JE, Dunbar KEA, Kevun Webb A, Dodd ME, Lorraine Martin S, Cherie Millar B, Scott CJ, Crowe M, Stuart Elborn J: PCR-Based Detection and Identification of Burkholderia cepacia Complex Pathogens in Sputum from Cystic Fibrosis Patients. J Clin Microbiol. 2001, 39 (12): 4247-4255. 10.1128/JCM.39.12.4247-4255.2001.CrossRefPubMedPubMedCentral
15.
go back to reference Drvinek P, Hrbackova H, Cinek O, Bartosova J, Nyc O, Nemec A, Pohunek P: Direct PCR Detection of Burkholderia cepacia complex and identification of Its Genomovars by Using Sputum as Source of DNA. J Clin Microbiol. 2002, 40 (9): 3485-3888. 10.1128/JCM.40.9.3485-3488.2002.CrossRefPubMedCentral Drvinek P, Hrbackova H, Cinek O, Bartosova J, Nyc O, Nemec A, Pohunek P: Direct PCR Detection of Burkholderia cepacia complex and identification of Its Genomovars by Using Sputum as Source of DNA. J Clin Microbiol. 2002, 40 (9): 3485-3888. 10.1128/JCM.40.9.3485-3488.2002.CrossRefPubMedCentral
16.
go back to reference National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. 1997, National Committee for Clinical Laboratory Standards, Villanova, Pa, 4 National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. 1997, National Committee for Clinical Laboratory Standards, Villanova, Pa, 4
17.
go back to reference Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2002. Bethesda. 2003 Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2002. Bethesda. 2003
18.
go back to reference Jones AM, Dodd ME, Govan JRW, Barcus V, Doherty CJ, Morris J, Webb AK: Burkholderia cenocepacia and Burkholderia multivorans : influence on survival in Cystic Fibrosis. Thorax. 2004, 59: 948-51. 10.1136/thx.2003.017210.CrossRefPubMedPubMedCentral Jones AM, Dodd ME, Govan JRW, Barcus V, Doherty CJ, Morris J, Webb AK: Burkholderia cenocepacia and Burkholderia multivorans : influence on survival in Cystic Fibrosis. Thorax. 2004, 59: 948-51. 10.1136/thx.2003.017210.CrossRefPubMedPubMedCentral
19.
go back to reference Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S: Identification and Antimicrobial Susceptibility of Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis. J Clin Microbiol. 2001, 39 (11): 3942-3945. 10.1128/JCM.39.11.3942-3945.2001.CrossRefPubMedPubMedCentral Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S: Identification and Antimicrobial Susceptibility of Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis. J Clin Microbiol. 2001, 39 (11): 3942-3945. 10.1128/JCM.39.11.3942-3945.2001.CrossRefPubMedPubMedCentral
20.
go back to reference Denton M, Kerr KG: Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998, 11 (1): 57-80.PubMedPubMedCentral Denton M, Kerr KG: Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998, 11 (1): 57-80.PubMedPubMedCentral
21.
go back to reference Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S: Identification and Antimicrobial Susceptibility of Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis. J Clin Microbiol. 2001, 39 (11): 3942-3945. 10.1128/JCM.39.11.3942-3945.2001.CrossRefPubMedPubMedCentral Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S: Identification and Antimicrobial Susceptibility of Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis. J Clin Microbiol. 2001, 39 (11): 3942-3945. 10.1128/JCM.39.11.3942-3945.2001.CrossRefPubMedPubMedCentral
22.
go back to reference Heath DG, Hohneker K, Carriker C, Smith K, Routh J, LiPuma JJ, Aria RM, Weber D, Gilligan PH: Six-year Molecular Analysis of Burkholderia cepacia Complex Isolates among Cystic Fibrosis Patients at a referral Center for Lung Transplantation. J Clin Microbiol. 2002, 40 (4): 1188-1193. 10.1128/JCM.40.4.1188-1193.2002.CrossRefPubMedPubMedCentral Heath DG, Hohneker K, Carriker C, Smith K, Routh J, LiPuma JJ, Aria RM, Weber D, Gilligan PH: Six-year Molecular Analysis of Burkholderia cepacia Complex Isolates among Cystic Fibrosis Patients at a referral Center for Lung Transplantation. J Clin Microbiol. 2002, 40 (4): 1188-1193. 10.1128/JCM.40.4.1188-1193.2002.CrossRefPubMedPubMedCentral
23.
go back to reference Biddick R, Spilker T, Martin A, LiPuma JJ: Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett. 2003, 228 (1): 57-62. 10.1016/S0378-1097(03)00724-9.CrossRefPubMed Biddick R, Spilker T, Martin A, LiPuma JJ: Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett. 2003, 228 (1): 57-62. 10.1016/S0378-1097(03)00724-9.CrossRefPubMed
24.
go back to reference Manno G, Dalmastri C, Tabacchioni S, Vandamme P, Lorini R, Minicicci L, Romano L, Giannattasio A, Chiarini L, Bevivino A: Epidemiology and Clinical Course of Burkholderia cepacia Complex Infections, Particularly Those Caused by Different Burkholderia cenocepacia Strains, among Patients Attending an Italian Cystic Fibrosis Center. J Clin Microbiol. 2004, 42 (4): 1491-1497. 10.1128/JCM.42.4.1491-1497.2004.CrossRefPubMedPubMedCentral Manno G, Dalmastri C, Tabacchioni S, Vandamme P, Lorini R, Minicicci L, Romano L, Giannattasio A, Chiarini L, Bevivino A: Epidemiology and Clinical Course of Burkholderia cepacia Complex Infections, Particularly Those Caused by Different Burkholderia cenocepacia Strains, among Patients Attending an Italian Cystic Fibrosis Center. J Clin Microbiol. 2004, 42 (4): 1491-1497. 10.1128/JCM.42.4.1491-1497.2004.CrossRefPubMedPubMedCentral
25.
go back to reference Mahenthiralingam E, Bischof J, Byrne SK, Radomski C, Davies JE, Av-Gay Y, Vandamme P: DNA-Based Approaches for Identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, B.multivorans, B.stabilis and B.cepacia genomovars I and III. J Clin Microbiol. 2000, 38 (9): 3165-3173.PubMedPubMedCentral Mahenthiralingam E, Bischof J, Byrne SK, Radomski C, Davies JE, Av-Gay Y, Vandamme P: DNA-Based Approaches for Identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, B.multivorans, B.stabilis and B.cepacia genomovars I and III. J Clin Microbiol. 2000, 38 (9): 3165-3173.PubMedPubMedCentral
26.
go back to reference Coenye T, LiPuma JJ: Population structure analysis of Burkholderia cepacia genomovar III: varying degrees of genetic recombination characterize major clonal complexes. Microbiology. 2002, 149: 77-88. 10.1099/mic.0.25850-0.CrossRef Coenye T, LiPuma JJ: Population structure analysis of Burkholderia cepacia genomovar III: varying degrees of genetic recombination characterize major clonal complexes. Microbiology. 2002, 149: 77-88. 10.1099/mic.0.25850-0.CrossRef
27.
go back to reference LiPuma JJ, Spilker T, Gill LH, Campbell PW, Liu L, Mahenthiralingam E: Disproportionate distribution of Burkholderia cepacia complex species and trasmissibility markers in cystic fibrosis. Am J Respir Crit Care Med. 2001, 164: 92-96.CrossRefPubMed LiPuma JJ, Spilker T, Gill LH, Campbell PW, Liu L, Mahenthiralingam E: Disproportionate distribution of Burkholderia cepacia complex species and trasmissibility markers in cystic fibrosis. Am J Respir Crit Care Med. 2001, 164: 92-96.CrossRefPubMed
28.
go back to reference Schwab U, Gilligan P, Jaynes J, Henke D: In Vitro Activities of Designed Antimicrobial Peptides against Multidrug-Resistant Cystic Fibrosis Pathogens. Antimicrob Agents Chemother. 1999, 43 (6): 1435-1440.PubMedPubMedCentral Schwab U, Gilligan P, Jaynes J, Henke D: In Vitro Activities of Designed Antimicrobial Peptides against Multidrug-Resistant Cystic Fibrosis Pathogens. Antimicrob Agents Chemother. 1999, 43 (6): 1435-1440.PubMedPubMedCentral
29.
go back to reference Marchetti F, Giglio L, Candusso M, Faraguna D, Assael BM: Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol. 2004, 60: 67-74. 10.1007/s00228-004-0735-2.CrossRefPubMed Marchetti F, Giglio L, Candusso M, Faraguna D, Assael BM: Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol. 2004, 60: 67-74. 10.1007/s00228-004-0735-2.CrossRefPubMed
30.
go back to reference Saiman L, Siegel J: Infection control reccommendations for patients with cystic fibrosis: microbiology, important pathogens and infection control practices to prevent patient-to-patient transmission. Am J Infect Control. 2003, 3 (Suppl): Saiman L, Siegel J: Infection control reccommendations for patients with cystic fibrosis: microbiology, important pathogens and infection control practices to prevent patient-to-patient transmission. Am J Infect Control. 2003, 3 (Suppl):
Metadata
Title
Microbiology of airway disease in a cohort of patients with Cystic Fibrosis
Authors
Antonietta Lambiase
Valeria Raia
Mariassunta Del Pezzo
Angela Sepe
Vincenzo Carnovale
Fabio Rossano
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2006
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-6-4

Other articles of this Issue 1/2006

BMC Infectious Diseases 1/2006 Go to the issue